Bicara Therapeutics (BCAX) Operating Leases (2023 - 2026)

Bicara Therapeutics has reported Operating Leases for 4 years, with the latest figure at $301000.0 in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases changed N/A year-over-year to $301000.0; the trailing twelve-month figure through Mar 2026 stood at $301000.0 (changed N/A YoY), and the FY2025 full-year result was $593000.0, up 352.67% from the prior year.
• Operating Leases for Q1 2026 stood at $301000.0, down from $593000.0 in the prior quarter.
• The five-year high for Operating Leases was $1.2 million in Q2 2025, with the low at $131000.0 in Q4 2024.
• Historically, Operating Leases has averaged $511142.9 across 4 years, with a median of $372000.0 in 2023.
• Annual changes were most pronounced in 2024 — Operating Leases sank 64.78% — and 2025, when it soared 542.34%.
• Bicara Therapeutics' Operating Leases stood at $372000.0 in 2023, then slumped by 64.78% to $131000.0 in 2024, then soared by 352.67% to $593000.0 in 2025, then tumbled by 49.24% to $301000.0 in 2026.
• The last three Operating Leases figures came in at $301000.0 (Q1 2026), $593000.0 (Q4 2025), and $880000.0 (Q3 2025), per Business Quant data.